Mumbai: As precision oncology turns into more and more central to cancer care, fast and correct detection of genetic mutations is rising as a important issue in guiding treatment decisions. In a transfer geared toward accelerating entry to biomarker-driven therapies, Agilus Diagnostics has launched the automated Idylla molecular diagnostics system at its Goregaon laboratory in Mumbai, enabling detection of clinically related cancer mutations inside 2.5 to 3 hours—considerably sooner than standard molecular testing strategies that may take a number of days.
The event comes at a time when oncologists are more and more counting on molecular profiling to establish actionable biomarkers and tailor therapies to the genetic traits of particular person tumors. Sooner turnaround occasions might help clinicians provoke acceptable therapies sooner, significantly in instances the place treatment decisions are time-sensitive.
“The Idylla system is a completely built-in, cartridge-based molecular diagnostics platform that mixes pattern processing, nucleic acid extraction, amplification and detection right into a single automated workflow. By minimising handbook intervention and lowering pre-analytical variability, the platform is designed to ship extremely correct and reproducible outcomes whereas streamlining laboratory operations,” a press release mentioned.
The know-how allows fast detection of a number of clinically related genetic mutations that play a key position in cancer analysis and treatment choice. These embrace EGFR mutations, generally related to lung cancer in Indian and Asian populations; KRAS and NRAS, that are necessary biomarkers in colorectal and pancreatic cancers; and BRAF, discovered throughout a number of tumor sorts, together with melanoma and colorectal cancer.
Along with these established biomarkers, the platform additionally helps testing for rising markers comparable to Microsatellite Instability (MSI) and IDH1/IDH2 mutations. These biomarkers are more and more getting used to find out affected person eligibility for superior focused therapies and immunotherapies, reflecting the rising shift towards personalised cancer treatment.
Commenting on the launch, Dr. Anand Ok, MD & CEO, Agilus Diagnostics, mentioned, “The way forward for oncology lies not simply in superior therapies, however in the flexibility to ship quick, correct diagnoses that may information treatment decisions in actual time. The introduction of the Idylla system at our Goregaon facility considerably enhances our molecular diagnostics capabilities and strengthens our dedication to precision drugs. By enabling fast entry to important genomic insights, we purpose to empower clinicians with well timed, actionable data that may enhance treatment outcomes and increase entry to high quality cancer care.”
Dr. Kunal Sharma, Vice President and Head – Built-in Onco-Pathology, Agilus Diagnostics, famous that delivering actionable molecular insights inside hours can considerably affect affected person administration. He mentioned the platform’s capacity to detect key mutations with minimal handbook intervention and excessive analytical efficiency is especially priceless in conditions the place tissue samples are restricted and treatment decisions should be made shortly.
Consultants imagine that as focused therapies proceed to increase throughout a number of cancer sorts, the necessity for fast and dependable molecular testing will change into more and more necessary. Delays in biomarker identification can postpone treatment initiation, whereas sooner entry to genomic data might help clinicians match sufferers with essentially the most acceptable therapies earlier in the treatment journey.
The launch additional strengthens Agilus Diagnostics’ built-in oncology diagnostics ecosystem and underscores the rising position of superior molecular diagnostics in supporting biomarker-driven treatment pathways. As India continues to increase entry to precision drugs, improvements that shorten testing timelines could play a pivotal position in enhancing outcomes and advancing personalised cancer care.
Source link
#Rapid #cancer #mutation #testing #hours #accelerate #precision #treatment #decisions
